Dr. Karin Potoka of Noveome Biotherapeutics discusses a Phase I/II secretome-based biologic being studied for NEC in premature infants, and the manufacturing, regulatory and site strategy behind therapy development for rare neonatal disease. Learn more in this exclusive interview: buff.ly/zxax5Cr #Noveome #RegenerativeMedicine #Secretome #NecrotizingEnterocolitis #RareDisease

Which pharma companies are shaping the next phase of biopharma? Fast Company’s 2026 list spotlights innovators across HIV prevention, non-opioid pain, RNAi, vaccines, cancer and women’s health. See Xtalks’ breakdown of the top 10 most innovative pharma companies of 2026: buff.ly/zj1ChpY #Pharma #Biopharma #LifeSciences #DrugDevelopment #PharmaInnovation

New medtech layoff updates are live, including job cuts tied to J&J’s planned orthopedics separation and Carl Zeiss Meditec’s global cost-saving plan. Get details on the latest moves: buff.ly/M7CSkys #MedtechLayoffs #MedicalDevices #MedtechIndustry #MedtechNews

Navigate rare disease trial complexity without increasing burden with Florence Mowlem, PhD, Paula Brown Stafford, Matteo Lai and Jennifer Cook in this webinar hosted by uMotif. As protocols grow more complex, sponsors and sites face mounting pressure to protect data quality while reducing operational friction for participants and caregivers. This session explores how stronger participant-site partnerships and thoughtful technology strategies can improve engagement, retention, and execution across high-stakes rare disease studies. Register for this webinar to learn how to design with sites and patients in mind, reduce friction, and improve retention and data quality in complex trials: buff.ly/ER6vzNK #uMotif #LifeSciences #Biopharma #ClinicalTrials #RareDisease #PatientCentricity #ClinicalOperations #DigitalHealth #TrialInnovation #SiteEngagement #ParticipantRetention #DecentralizedTrials #ResearchSites #ClinicalResearch

Navigate competing clinical development priorities with Cheryl Silva in this webinar hosted by Premier Research. As trial complexity and budget pressure rise, sponsors are moving beyond one-size-fits-all outsourcing models to find the right balance of speed, cost control, internal capacity, and scope. This session explores how hybrid operating models can help clinical teams make smarter trade-offs, reshape the RFP process, and build CRO partnerships that are fit for purpose. Register for this webinar to learn how to evaluate operating model options, sharpen your clinical trial RFP strategy, and apply hybrid approaches in real-world programs: buff.ly/DDmNjc0 #PremierResearch #LifeSciences #Biopharma #ClinicalDevelopment #ClinicalTrials #CRO #OutsourcingStrategy #HybridOperatingModel #FunctionalServiceProvider #ClinicalOperations #DrugDevelopment #RFPStrategy #Biotech #Pharma

Transform supply chain disruption into resilient planning with Yury Yohana Gomez, Alex Moss and Rohit Bhutani in this webinar hosted by Microsoft. Biopharma supply networks face mounting pressure from volatility, compliance demands, and rising service expectations, while legacy planning models struggle to keep pace. This session explores how AI, real-time data, and scenario modeling can strengthen visibility, improve decision-making, and lower cost to serve across complex global operations. Register for this webinar to learn how AI can improve supply chain visibility, disruption response, and cost-compliant planning at scale: buff.ly/FUcb37a #Microsoft #LifeSciences #Biopharma #PharmaSupplyChain #SupplyChainResilience #ArtificialIntelligence #AdvancedAnalytics #DemandForecasting #InventoryOptimization #DigitalTwin #IntegratedBusinessPlanning #RegulatoryCompliance #Manufacturing #SupplyChainVisibility

Overcome life sciences supply chain bottlenecks with Simon Bowes in this webinar hosted by Blue Yonder. As global manufacturing networks grow more complex, even small breakdowns in CMO coordination, data visibility, or carrier performance can trigger costly delays across regulated supply chains. This session explores how multi-enterprise orchestration, sharper forecasting, and logistics precision can strengthen resilience, improve operational performance, and protect both margins and patient outcomes. Register for this webinar to learn how to reduce delays, improve forecast accuracy, and optimize cost-to-service across life sciences manufacturing: buff.ly/MTWwxnl #LifeSciences #Biopharma #SupplyChain #SupplyChainOrchestration #ManufacturingOperations #PharmaManufacturing #ForecastAccuracy #LogisticsPrecision #OperationalExcellence #InventoryOptimization #PatientOutcomes #CMOManagement #DigitalSupplyChain #BlueYonder

Accelerate advanced therapy readiness before delays compound with Lorraine Hicks, Dominic Clarke, PhD and Gwendolyn Erskine in this webinar hosted by Cryoport Systems. Early supply chain choices can either strengthen program momentum or create downstream regulatory, operational, and scalability challenges. For advanced therapy teams navigating cryopreservation, manufacturing complexity, and clinical progression, proactive strategy is essential to reduce risk and support long-term success. Register for this webinar to learn how early decisions can improve regulatory readiness, scalability, and defensible development planning: buff.ly/ibqkd6d #CryoportSystems #AdvancedTherapies #CellAndGeneTherapy #Biopharma #LifeSciences #SupplyChainStrategy #ClinicalLogistics #Cryopreservation #RegulatoryReadiness #TechnicalOperations #BiotechInnovation #ClinicalDevelopment #Commercialization

Investors are watching healthcare companies with clearer business fundamentals, stronger growth plans and public-market readiness. Our 2026 healthcare IPO tracker follows the companies going public across ER services and more: buff.ly/kmay8zv #HealthcareIPOs #EmergencyServices #HospitalCare #DigitalHealth #LifeSciences

Why do some drugs cost millions? Xtalks looks at the most expensive drugs in 2026, from Lenmeldy to Hemgenix, and explains how rare diseases, one-time gene therapies and complex manufacturing shape pricing. Read more: buff.ly/qOqsc6w #DrugPricing #GeneTherapy #RareDiseases #CellTherapy #PharmaNews

Chiesi’s Diego Ardigò shares what’s next in asthma and COPD R&D, and why the future of respiratory medicine depends on balancing innovation, patient experience and environmental sustainability. Listen now at buff.ly/eDfJIux 🎙️

Navigate oncology trial complexity under execution pressure with Andrew Zupnick, PhD, Heidi Gillenwater, MD, Elise Horvath Walsh, MD, VP and Victor Moreno, MD, PhD in this webinar hosted by Worldwide Clinical Trials Oncology. ASCO may shape scientific direction, but sponsors still have to convert insight into executable development strategy. As biomarker-driven approaches, novel modalities, AI, and multi-cohort designs raise complexity, success increasingly depends on early operational alignment across protocol design, feasibility, oversight, vendors, data flows, and global study execution. Register for this webinar to learn how ASCO 2026 insights can inform faster decisions, more feasible trial design, and stronger execution as oncology programs scale: buff.ly/uyg82gl #WorldwideClinicalTrials #Oncology #ClinicalTrials #OncologyDrugDevelopment #ClinicalOperations #Biomarkers #PrecisionMedicine #EarlyPhaseTrials #TrialExecution #ProtocolDesign #AIInHealthcare #Biopharma #LifeSciences #DrugDevelopment

Master patient interview planning before data quality breaks down with Jens Harald Kongsø, MSc in Economics and Christian Holm, MSc in Computer Engineering in this webinar hosted by CLINIGMA. As regulators place greater emphasis on the patient voice, sponsors face rising pressure to ensure interview data is planned for compliance, credibility, and operational feasibility from the start. This session examines where teams go wrong early, how ICH-GCP E6(R3) is raising expectations, and what a structured approach means for patient safety and trial data integrity. Register for this webinar to learn how to plan in-trial interviews for stronger data readiness, safer execution, and more confident vendor selection: buff.ly/yjtypzp #Clinigma #LifeSciences #Biopharma #ClinicalTrials #PatientVoice #PatientInterviews #ClinicalOperations #RegulatoryCompliance #DataIntegrity #PatientSafety #ICHGCP #FDA #EMA #TrialReadiness

Pharma and biotech M&A activity has been heating up this spring, with Eli Lilly especially active on the deal making front. With deals spanning genetic medicines, blood cancers, CAR-T, ADCs and sleep-wake disorders, take a look at the latest M&As in Xtalks’ deal watcher report. Read more: buff.ly/N3l5H5r #Pharma #Biotech #PharmaM&A #LifeSciences

GLP-1s still lead the obesity drug market, but 2026 is bringing more players into view. Our latest blog looks at 10 companies advancing pills, dual agonists, amylin drugs and next-gen metabolic candidates. Read more: hhttps://buff.ly/zMT51eO #ObesityDrugs #GLP1 #Biotech #Pharma #MetabolicHealth

What’s next for regulatory science, clinical research and drug safety in Canada? This October, the DIA Canada Annual Meeting 2026 will bring together regulators, researchers and industry leaders to discuss emerging challenges, evolving practices and new opportunities shaping healthcare product development. 👉 Learn more and register at {URL} #ClinicalResearch #RegulatoryAffairs #Pharmacovigilance #DrugSafety #Pharma #MedTech #DIACanada2026

Foreign investment in UK life sciences jumped 164%, but which companies are standing out as employers? Our blog looks at six pharma and biotech names ranked by FT/Statista, from AstraZeneca to Thermo Fisher. Read more: buff.ly/Dd6lQGB #Pharma #Biotech #LifeSciences #UKLifeSciences #ClinicalResearch

Which pharma companies are shaping the next phase of biopharma? Fast Company’s 2026 list spotlights innovators across HIV prevention, non-opioid pain, RNAi, vaccines, cancer and women’s health. See Xtalks’ breakdown of the top 10 most innovative pharma companies of 2026: buff.ly/zj1ChpY #Pharma #Biopharma #LifeSciences #DrugDevelopment #PharmaInnovation

Master MRD execution challenges in oncology development with Wael Harb, MD, MBA, Patrick Melvin, Jacquelyn Ritchie, Muaiad Kittaneh, MD, MBA, FACP, Rob Lentz and David Shames in this webinar hosted by Syneos Health. As MRD becomes a more decisive input in oncology development, execution quality is what determines whether biomarker data are actionable or simply observational. This session explores how protocol design, site readiness, sample workflows, laboratory alignment, and cross-functional governance can strengthen data integrity, reduce operational risk, and improve downstream clinical, regulatory, and commercial value. Register for this webinar to learn how to turn MRD strategy into executable trial design and align teams early to improve data quality, regulatory positioning, and commercial impact: buff.ly/XaqcsDq #SyneosHealth #OncologyTrials #MinimalResidualDisease #MRD #Biomarkers #ClinicalTrials #OncologyDevelopment #HematologicMalignancies #SolidTumors #ClinicalOperations #RegulatoryStrategy #MarketAccess #Biopharma #LifeSciences

Meet Xtalks Featured Community Member Dr. Laura Saltonstall, MD, MBA, Vice President, Medical Affairs, Immunology at Sobi. Combining clinical expertise with personal experience in rare disease, she is helping translate science into meaningful impact for patients and families. Read more: buff.ly/IuALdD9 #MedicalAffairs #RareDisease #Immunology #PatientCentricity #XtalksCommunity